# A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

> **NCT06703892** · PHASE1 · RECRUITING · sponsor: **GenomeFrontier Therapeutics TW Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma Relapsed
- Diffuse Large B Cell Lymphoma Refractory
- Follicular Lymphoma ( FL)
- Primary Mediastinal Large B-Cell Lymphoma-Refractory
- Primary Mediastinal Large B-Cell Lymphoma-Recurrent
- High-grade B-cell Lymphoma (HGBCL)

## Interventions

- **BIOLOGICAL:** GF-CART01
- **BIOLOGICAL:** GF-CART01
- **BIOLOGICAL:** GF-CART01

## Key facts

- **NCT ID:** NCT06703892
- **Lead sponsor:** GenomeFrontier Therapeutics TW Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-09
- **Primary completion:** 2027-03
- **Final completion:** 2027-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06703892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06703892, "A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06703892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*